Whole-exome sequencing in syndromic craniosynostosis increases diagnostic yield and identifies candidate genes in osteogenic signaling pathways.
Elin TønneBernt Johan Due-TønnessenMagnus Dehli VigelandSilja Svanstrøm AmundsenTeodora RibarskaPamela Marika ÅstenYing ShengEirik HelsethGregor Duncan GilfillanInger-Lise MeroKetil Riddervold HeimdalPublished in: American journal of medical genetics. Part A (2022)
Craniosynostosis (CS) is a common congenital anomaly defined by premature fusion of one or more cranial sutures. Syndromic CS involves additional organ anomalies or neurocognitive deficits and accounts for 25%-30% of the cases. In a recent population-based study by our group, 84% of the syndromic CS cases had a genetically verified diagnosis after targeted analyses. A number of different genetic causes were detected, confirming that syndromic CS is highly heterogeneous. In this study, we performed whole-exome sequencing of 10 children and parents from the same cohort where previous genetic results were negative. We detected pathogenic, or likely pathogenic, variants in four additional genes (NFIA, EXTL3, POLR2A, and FOXP2) associated with rare conditions. In two of these (POLR2A and FOXP2), CS has not previously been reported. We further detected a rare predicted damaging variant in SH3BP4, which has not previously been related to human disease. All findings were clustered in genes involved in the pathways of osteogenesis and suture patency. We conclude that whole-exome sequencing expands the list of genes associated with syndromic CS, and provides new candidate genes in osteogenic signaling pathways.
Keyphrases
- intellectual disability
- genome wide
- signaling pathway
- regulatory t cells
- mesenchymal stem cells
- copy number
- bone marrow
- autism spectrum disorder
- endothelial cells
- bipolar disorder
- pi k akt
- gene expression
- cell proliferation
- cancer therapy
- epithelial mesenchymal transition
- transcription factor
- pluripotent stem cells
- drug induced